말 건강 관리 시장

Equine Healthcare Market- Scope of Report

TMR's report on the global Equine Healthcare Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Equine Healthcare Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Equine Healthcare Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Equine Healthcare Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Equine Healthcare Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Equine Healthcare Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Equine Healthcare Market .

The report delves into the competitive landscape of the global Equine Healthcare Market . Key players operating in the global Equine Healthcare Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Equine Healthcare Marketprofiled in this report.

Key Questions Answered in Global Equine Healthcare MarketReport:

• What are the opportunities in the global Equine Healthcare Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Equine Healthcare Market- Research Objectives and Research Approach

The comprehensive report on the global Equine Healthcare Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Equine Healthcare Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Equine Healthcare Market .

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Equine Healthcare Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Equine Healthcare Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Equine Healthcare Market Trends
• 5.2. Regulatory Scenario Across Key Regions/Countries
• 5.3. PESTEL Analysis
• 5.4. PORTER's Analysis
• 5.5. Pipeline Analysis for Equine Drugs and Vaccines
• 5.6. Pricing Trends of Equine Health Care Products
• 5.7. Key Industry Events
• 5.8. Epidemiology Analysis Across Key Regions/Countries
• 5.9. Go-to-Market Strategy for New Market Entrants
• 5.10. Key Shortlisting Metrics for End-users
• 5.11. Benchmarking of the Products Offered by the Leading Competitors

6. Global Equine Healthcare Market Analysis and Forecasts, By Product Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Product Type, 2020 to 2035
  • 6.3.1. Therapeutics
    • 6.3.1.1. Drugs
      • 6.3.1.1.1. Anti-Infective
      • 6.3.1.1.2. Anti-inflammatory
      • 6.3.1.1.3. Parasiticides
      • 6.3.1.1.4. Others
    • 6.3.1.2. Vaccine
      • 6.3.1.2.1. Inactivated
      • 6.3.1.2.2. Live Attenuated
      • 6.3.1.2.3. Recombinant
      • 6.3.1.2.4. Others
    • 6.3.1.3. Supplemental Feed additives
      • 6.3.1.3.1. Proteins and amino acids
      • 6.3.1.3.2. Vitamins
      • 6.3.1.3.3. Enzymes
      • 6.3.1.3.4. Minerals
      • 6.3.1.3.5. Others
    • 6.3.1.4. Regenerative Medicine
  • 6.3.2. Diagnostics
    • 6.3.2.1. Diagnostic Kits & Reagents
    • 6.3.2.2. Instruments
• 6.4. Market Attractiveness By Product Type

7. Global Equine Healthcare Market Analysis and Forecasts, By Indication

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Indication, 2020 to 2035
  • 7.3.1. Equine Influenza
  • 7.3.2. Equine Herpes virus (EHV)
  • 7.3.3. Equine Encephalomyelitis
  • 7.3.4. West Nile Virus
  • 7.3.5. Equine Rabies
  • 7.3.6. Potomac Horse Fever
  • 7.3.7. Osteoarthritis
  • 7.3.8. Tetanus
  • 7.3.9. Others
• 7.4. Market Attractiveness By Indication

8. Global Equine Healthcare Market Analysis and Forecasts, By End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By End-user, 2020 to 2035
  • 8.3.1. Veterinary Hospitals
  • 8.3.2. Equine Clinics
  • 8.3.3. Equestrian Facilities
  • 8.3.4. Others
• 8.4. Market Attractiveness By End-user

9. Global Equine Healthcare Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Country/Region

10. North America Equine Healthcare Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Product Type, 2020 to 2035
  • 10.2.1. Therapeutics
    • 10.2.1.1. Drugs
      • 10.2.1.1.1. Anti-Infective
      • 10.2.1.1.2. Anti-inflammatory
      • 10.2.1.1.3. Parasiticides
      • 10.2.1.1.4. Others
    • 10.2.1.2. Vaccine
      • 10.2.1.2.1. Inactivated
      • 10.2.1.2.2. Live Attenuated
      • 10.2.1.2.3. Recombinant
      • 10.2.1.2.4. Others
    • 10.2.1.3. Supplemental Feed additives
      • 10.2.1.3.1. Proteins and amino acids
      • 10.2.1.3.2. Vitamins
      • 10.2.1.3.3. Enzymes
      • 10.2.1.3.4. Minerals
      • 10.2.1.3.5. Others
    • 10.2.1.4. Regenerative Medicine
  • 10.2.2. Diagnostics
    • 10.2.2.1. Diagnostic Kits & Reagents
    • 10.2.2.2. Instruments
• 10.3. Market Value Forecast By Indication, 2020 to 2035
  • 10.3.1. Equine Influenza
  • 10.3.2. Equine Herpes virus (EHV)
  • 10.3.3. Equine Encephalomyelitis
  • 10.3.4. West Nile Virus
  • 10.3.5. Equine Rabies
  • 10.3.6. Potomac Horse Fever
  • 10.3.7. Osteoarthritis
  • 10.3.8. Tetanus
  • 10.3.9. Others
• 10.4. Market Value Forecast By End-user, 2020 to 2035
  • 10.4.1. Veterinary Hospitals
  • 10.4.2. Equine Clinics
  • 10.4.3. Equestrian Facilities
  • 10.4.4. Others
• 10.5. Market Value Forecast By Country, 2020 to 2035
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Product Type
  • 10.6.2. By Indication
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Equine Healthcare Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Product Type, 2020 to 2035
  • 11.2.1. Therapeutics
    • 11.2.1.1. Drugs
      • 11.2.1.1.1. Anti-Infective
      • 11.2.1.1.2. Anti-inflammatory
      • 11.2.1.1.3. Parasiticides
      • 11.2.1.1.4. Others
    • 11.2.1.2. Vaccine
      • 11.2.1.2.1. Inactivated
      • 11.2.1.2.2. Live Attenuated
      • 11.2.1.2.3. Recombinant
      • 11.2.1.2.4. Others
    • 11.2.1.3. Supplemental Feed additives
      • 11.2.1.3.1. Proteins and amino acids
      • 11.2.1.3.2. Vitamins
      • 11.2.1.3.3. Enzymes
      • 11.2.1.3.4. Minerals
      • 11.2.1.3.5. Others
    • 11.2.1.4. Regenerative Medicine
  • 11.2.2. Diagnostics
    • 11.2.2.1. Diagnostic Kits & Reagents
    • 11.2.2.2. Instruments
• 11.3. Market Value Forecast By Indication, 2020 to 2035
  • 11.3.1. Equine Influenza
  • 11.3.2. Equine Herpes virus (EHV)
  • 11.3.3. Equine Encephalomyelitis
  • 11.3.4. West Nile Virus
  • 11.3.5. Equine Rabies
  • 11.3.6. Potomac Horse Fever
  • 11.3.7. Osteoarthritis
  • 11.3.8. Tetanus
  • 11.3.9. Others
• 11.4. Market Value Forecast By End-user, 2020 to 2035
  • 11.4.1. Veterinary Hospitals
  • 11.4.2. Equine Clinics
  • 11.4.3. Equestrian Facilities
  • 11.4.4. Others
• 11.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Switzerland
  • 11.5.7. The Netherlands
  • 11.5.8. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Product Type
  • 11.6.2. By Indication
  • 11.6.3. By End-user
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Equine Healthcare Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Product Type, 2020 to 2035
  • 12.2.1. Therapeutics
    • 12.2.1.1. Drugs
      • 12.2.1.1.1. Anti-Infective
      • 12.2.1.1.2. Anti-inflammatory
      • 12.2.1.1.3. Parasiticides
      • 12.2.1.1.4. Others
    • 12.2.1.2. Vaccine
      • 12.2.1.2.1. Inactivated
      • 12.2.1.2.2. Live Attenuated
      • 12.2.1.2.3. Recombinant
      • 12.2.1.2.4. Others
    • 12.2.1.3. Supplemental Feed additives
      • 12.2.1.3.1. Proteins and amino acids
      • 12.2.1.3.2. Vitamins
      • 12.2.1.3.3. Enzymes
      • 12.2.1.3.4. Minerals
      • 12.2.1.3.5. Others
    • 12.2.1.4. Regenerative Medicine
  • 12.2.2. Diagnostics
    • 12.2.2.1. Diagnostic Kits & Reagents
    • 12.2.2.2. Instruments
• 12.3. Market Value Forecast By Indication, 2020 to 2035
  • 12.3.1. Equine Influenza
  • 12.3.2. Equine Herpes virus (EHV)
  • 12.3.3. Equine Encephalomyelitis
  • 12.3.4. West Nile Virus
  • 12.3.5. Equine Rabies
  • 12.3.6. Potomac Horse Fever
  • 12.3.7. Osteoarthritis
  • 12.3.8. Tetanus
  • 12.3.9. Others
• 12.4. Market Value Forecast By End-user, 2020 to 2035
  • 12.4.1. Veterinary Hospitals
  • 12.4.2. Equine Clinics
  • 12.4.3. Equestrian Facilities
  • 12.4.4. Others
• 12.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. South Korea
  • 12.5.5. Australia & New Zealand
  • 12.5.6. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Product Type
  • 12.6.2. By Indication
  • 12.6.3. By End-user
  • 12.6.4. By Country/Sub-region

13. Latin America Equine Healthcare Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Product Type, 2020 to 2035
  • 13.2.1. Therapeutics
    • 13.2.1.1. Drugs
      • 13.2.1.1.1. Anti-Infective
      • 13.2.1.1.2. Anti-inflammatory
      • 13.2.1.1.3. Parasiticides
      • 13.2.1.1.4. Others
    • 13.2.1.2. Vaccine
      • 13.2.1.2.1. Inactivated
      • 13.2.1.2.2. Live Attenuated
      • 13.2.1.2.3. Recombinant
      • 13.2.1.2.4. Others
    • 13.2.1.3. Supplemental Feed additives
      • 13.2.1.3.1. Proteins and amino acids
      • 13.2.1.3.2. Vitamins
      • 13.2.1.3.3. Enzymes
      • 13.2.1.3.4. Minerals
      • 13.2.1.3.5. Others
    • 13.2.1.4. Regenerative Medicine
  • 13.2.2. Diagnostics
    • 13.2.2.1. Diagnostic Kits & Reagents
    • 13.2.2.2. Instruments
• 13.3. Market Value Forecast By Indication, 2020 to 2035
  • 13.3.1. Equine Influenza
  • 13.3.2. Equine Herpes virus (EHV)
  • 13.3.3. Equine Encephalomyelitis
  • 13.3.4. West Nile Virus
  • 13.3.5. Equine Rabies
  • 13.3.6. Potomac Horse Fever
  • 13.3.7. Osteoarthritis
  • 13.3.8. Tetanus
  • 13.3.9. Others
• 13.4. Market Value Forecast By End-user, 2020 to 2035
  • 13.4.1. Veterinary Hospitals
  • 13.4.2. Equine Clinics
  • 13.4.3. Equestrian Facilities
  • 13.4.4. Others
• 13.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Argentina
  • 13.5.4. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Product Type
  • 13.6.2. By Indication
  • 13.6.3. By End-user
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Equine Healthcare Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Product Type, 2020 to 2035
  • 14.2.1. Therapeutics
    • 14.2.1.1. Drugs
      • 14.2.1.1.1. Anti-Infective
      • 14.2.1.1.2. Anti-inflammatory
      • 14.2.1.1.3. Parasiticides
      • 14.2.1.1.4. Others
    • 14.2.1.2. Vaccine
      • 14.2.1.2.1. Inactivated
      • 14.2.1.2.2. Live Attenuated
      • 14.2.1.2.3. Recombinant
      • 14.2.1.2.4. Others
    • 14.2.1.3. Supplemental Feed additives
      • 14.2.1.3.1. Proteins and amino acids
      • 14.2.1.3.2. Vitamins
      • 14.2.1.3.3. Enzymes
      • 14.2.1.3.4. Minerals
      • 14.2.1.3.5. Others
    • 14.2.1.4. Regenerative Medicine
  • 14.2.2. Diagnostics
    • 14.2.2.1. Diagnostic Kits & Reagents
    • 14.2.2.2. Instruments
• 14.3. Market Value Forecast By Indication, 2020 to 2035
  • 14.3.1. Equine Influenza
  • 14.3.2. Equine Herpes virus (EHV)
  • 14.3.3. Equine Encephalomyelitis
  • 14.3.4. West Nile Virus
  • 14.3.5. Equine Rabies
  • 14.3.6. Potomac Horse Fever
  • 14.3.7. Osteoarthritis
  • 14.3.8. Tetanus
  • 14.3.9. Others
• 14.4. Market Value Forecast By End-user, 2020 to 2035
  • 14.4.1. Veterinary Hospitals
  • 14.4.2. Equine Clinics
  • 14.4.3. Equestrian Facilities
  • 14.4.4. Others
• 14.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Product Type
  • 14.6.2. By Indication
  • 14.6.3. By End-user
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2024)
• 15.3. Company Profiles
  • 15.3.1. Zoetis
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Arthrex, Inc.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. Dechra Pharmaceuticals
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Boehringer Ingelheim Animal Health USA Inc.
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. Ceva
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. Heska Corporation
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. Merck & Co., Inc.,
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Financial Overview
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Esaote SpA
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Financial Overview
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. IDEXX
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Financial Overview
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. Covetrus
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Financial Overview
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments
  • 15.3.11. Elanco
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Financial Overview
    • 15.3.11.3. Financial Overview
    • 15.3.11.4. Business Strategies
    • 15.3.11.5. Recent Developments
  • 15.3.12. Cargill, Incorporated
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Financial Overview
    • 15.3.12.3. Financial Overview
    • 15.3.12.4. Business Strategies
    • 15.3.12.5. Recent Developments
  • 15.3.13. Santa Cruz Biotechnology Inc.
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Financial Overview
    • 15.3.13.3. Financial Overview
    • 15.3.13.4. Business Strategies
    • 15.3.13.5. Recent Developments
  • 15.3.14. Other Prominent Players
    • 15.3.14.1. Company Overview
    • 15.3.14.2. Financial Overview
    • 15.3.14.3. Financial Overview
    • 15.3.14.4. Business Strategies
    • 15.3.14.5. Recent Developments